Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Publication|Videos|January 8, 2024
Maintaining a Strong Company Culture Through Difficult Times
Author(s)Societal CDMO
Societal™ CDMO's J. David Enloe and Erica Raether discuss the fundamentals of maintaining a strong company culture during times of change.
Change, particularly during difficult economic seasons, is inevitable and can pose a threat to the values that define an organization’s culture. A strong culture supports the organization’s mission and goals while keeping team members aligned, engaged, and motivated. Ensuring your company’s culture remains strong during difficult times starts with a few fundamentals.
In this video, sponsored by Societal™ CDMO and presented by Pharmaceutical Technology, J. David Enloe, President and CEO, and Erica Raether, Senior Vice President and Chief People Officer, both at Societal™ CDMO, share their insights surrounding how companies can ensure their values are being represented in daily interactions and communications.
Related to this article
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Bill Williams, AAPS, compares KinetiSol and spray drying for amorphous solid dispersions, covering 75% drug loading, pill burden, weakly basic drug release, and process limits.
Trending on Pharmaceutical Technology
1
FDA/CMS Gene Editing Guidance Shifts Evidence to CMC Teams
2
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
3
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
4
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
5